FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:835-836 February 24, 2005 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Barnett, A. H. PubMed Citation

To the Editor: Barnett et al. (Nov. 4 issue)¹ compared telmisartan and enalapril in type 2 diabetic nephropathy, without reporting or adjusting for certain major risk factors associated with diabetic nephropathy: glycemic control and hyperlipidemia. They assessed blood-pressure changes as a secondary end point, but their results indicate important issues regarding the extent to which their study can be generalized.

It is not clear why the target blood pressure was initially less than 160/90 mm Hg and what the subsequent, lower targets were during the study. The currently recommended blood-pressure goal for antihypertensive therapy in patients with diabetic nephropathy is . . . [Full Text of this Article]

This article has been cited by other articles:

• Rossing, P., Parving, H.-H., de Zeeuw, D. (2006). Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?. Nephrol Dial Transplant 21: 2354-2357 [Full Text]